La FDA ha aprobado Pasatru, un anticuerpo monoclonal dirigido a mutación en ACVR1 (garetosmab-grts) para tratar la fibrodisplasia osificante progresiva (FOP).

Rare Disease Drug Approvals CDER’s ARC Program | Center for Drug Evaluation and Research https://www.fda.gov/about-fda/accelerating-rare-disease-cures-arc-program/rare-disease-drug-approvals?utm_medium=email&_hsenc=p2ANqtz--PBA6stclF4JLxTA8SLwald4eFgFy675GDW4uRpSEpRhHll3YNxHBBb0fVgGGmSypBQfdx5WeBGvxfg42YlAuV2XOs1g&_hsmi=144267033&utm_content=144270294&utm_source=hs_email